Sustained complete molecular response after imatinib discontinuation in a patient with chronic myeloid leukemia not previously exposed to interferon alpha

被引：23

作者：

Verma, Dushyant ^{[1
]}

Kantarjian, Hagop ^{[1
]}

Jain, Nitin ^{[1
]}

Cortes, Jorge ^{[1
]}

机构：

[1] Univ Texas Houston, MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA

来源：

LEUKEMIA & LYMPHOMA | 2008年 / 49卷 / 07期

关键词：

D O I：

10.1080/10428190802043903

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

[No abstract available]

引用

页码：1399 / 1402

页数：4

共 13 条

[1] Chronic myeloid leukemia and interferon-α:: a study of complete cytogenetic responders [J].

Bonifazi, F ;

de Vivo, A ;

Rosti, G ;

Guilhot, F ;

Guilhot, J ;

Trabacchi, E ;

Hehlmann, R ;

Hochhaus, A ;

Shepherd, PCA ;

Steegmann, JL ;

Kluin-Nelemans, HC ;

Thaler, J ;

Simonsson, B ;

Louwagie, A ;

Reiffers, J ;

Mahon, FX ;

Montefusco, E ;

Alimena, G ;

Hasford, J ;

Richards, S ;

Saglio, G ;

Testoni, N ;

Martinelli, G ;

Tura, S ;

Baccarani, M .

BLOOD, 2001, 98 (10) :3074-3081

[2] Discontinuation of imatinib therapy after achievement of complete molecular response in a Ph plus CML patient treated while in long lasting complete cytogenetic remission (CCR) induced by interferon [J].

Breccia, M. ;

Diverio, D. ;

Pane, F. ;

Nanni, M. ;

Russo, E. ;

Biondo, F. ;

Frustaci, A. ;

Gentilini, F. ;

Alimena, G. .

LEUKEMIA RESEARCH, 2006, 30 (12) :1577-1579

[3] To the editor: Discontinuation of imatinib therapy after achieving a molecular response [J].

Cortes, J ;

O'Brien, S ;

Kantarjian, H .

BLOOD, 2004, 104 (07) :2204-2205

[4] Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia [J].

Hughes, TP ;

Kaeda, J ;

Branford, S ;

Rudzki, Z ;

Hochhaus, A ;

Hensley, ML ;

Gathmann, I ;

Bolton, AE ;

van Hoomissen, IC ;

Goldman, JM ;

Radich, JP ;

Taylor, K ;

Durrant, S ;

Schwarer, A ;

Joske, D ;

Seymour, J ;

Grigg, A ;

Ma, D ;

Arthur, C ;

Bradstock, K ;

Joshua, D ;

Lechner, K ;

Verhoef, G ;

Louwagie, A ;

Martiat, P ;

Straetmans, N ;

Bosly, A ;

Shepherd, J ;

Shustik, C ;

Lipton, J ;

Kovacs, DM ;

Turner, AR ;

Nielsen, JL ;

Birgens, H ;

Bjerrum, OW ;

Guilhot, F ;

Reiffers, J ;

Rousselot, P ;

Facon, T ;

Harousseau, JL ;

Tulliez, M ;

Guerci, A ;

Blaise, D ;

Maloisel, F ;

Michallet, M ;

Fischer, T ;

Hossfeld, D ;

Mertelsmann, R ;

Andreesen, R ;

Nerl, C .

NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (15) :1423-1432

[5] High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia [J].

Kantarjian, H ;

Talpaz, M ;

O'Brien, SS ;

Garcia-Manero, G ;

Verstovsek, S ;

Giles, F ;

Rios, MB ;

Shan, JQ ;

Letvak, L ;

Thomas, D ;

Faderl, S ;

Ferrajoli, A ;

Cortes, J .

BLOOD, 2004, 103 (08) :2873-2878

[6] Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-α [J].

Kantarjian, HM ;

Cortes, JE ;

O'Brien, S ;

Luthra, R ;

Giles, F ;

Verstovsek, S ;

Facerl, S ;

Thomas, D ;

Garcia-Manero, G ;

Rios, MB ;

Shan, J ;

Jones, D ;

Talpaz, M .

BLOOD, 2004, 104 (07) :1979-1988

[7] Complete cytogenetic and molecular responses to interferon-α-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis [J].

Kantarjian, HM ;

O'Brien, S ;

Cortes, JE ;

Shan, JQ ;

Giles, FJ ;

Rios, MB ;

Faderl, SH ;

Wierda, WG ;

Ferrajoli, A ;

Verstovsek, S ;

Keating, MJ ;

Freireieh, EJ ;

Talpaz, M .

CANCER, 2003, 97 (04) :1033-1041

[8] Follow-up of complete cytogenetic remission in patients with chronic myeloid leukemia after cessation of interferon alfa [J].

Mahon, FX ;

Delbel, X ;

Cony-Makhoul, P ;

Fabères, C ;

Boiron, JM ;

Barthe, C ;

Bilhou-Nabéra, C ;

Pigneux, A ;

Marit, G ;

Reiffers, J .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (01) :214-220

[9] Divergent clinical outcome in two CML patients who discontinued imatinib therapy after achieving a molecular remission [J].

Mauro, MJ ;

Druker, BJ ;

Maziarz, RT .

LEUKEMIA RESEARCH, 2004, 28 :S71-S73

[10]

Merante S, 2005, HAEMATOLOGICA, V90, P979

← 1 2 →